TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32320100
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (preoperative education, postoperative abdominal massage, and polyethylene glycol 4,000)
Study: 32320100
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment and Preoperative education only
Study: 33583000
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention (individual nutrition counseling) aiming for daily protein intake of 1.0-1.2 g/kg body weight, energy intake of 25-30 kcal/kg body weight/day, and serum vitamin D concentration ≥ 75 mmol/L
Study: 32067684
Drug: Experimental induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy (eight courses in total)
Study: 32067684
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy with six chemotherapy courses
Study: 32067684
Drug: Experimental induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy
Study: 34656952
Drug: Skin roasted
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin roasted peanuts (SRP, 25 g/day)
Study: 34656952
Drug: Peanut butter
Normalized name: Zbar Peanut Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut butter (PB, 32 g/day)
Study: 34656952
Drug: Control butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control butter (CB, 32 g/day)
Study: 34077818
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of docetaxel
Study: 36735400
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily for 12 months)
Study: 36735400
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 12 months)
Study: 32527268
Drug: Real dual‐tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real dual‐tDCS (2 mA for 20 mins) with concurrent paretic hand exercise
Study: 32466854
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000-unit pearl weekly for 4 weeks prior to the operation
Study: 34653566
Drug: Intelligent insole
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intelligent insole system with pressure-sensing insoles and digital watch, worn during all daily activity for 18 months.
Study: 35193445
Drug: Intensive physiotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive physiotherapy (twice-daily)
Study: 35193445
Drug: Standard physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiotherapy (once-daily)
Study: 33433575
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg sodium nitrite
Study: 33433575
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sodium nitrite
Study: 36104235
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day of empagliflozin
Study: 36104235
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day of empagliflozin
Study: 33009281
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac (Yellox)
Study: 33009281
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (bromfenac and dexamethasone)
Study: 33150227
Drug: HIV/AIDS knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV/AIDS knowledge assessment through a self‐administered questionnaire
Study: 33058961
Drug: Per log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per log ng/mL higher serum leptin
Study: 34807249
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group informed about 17 Japanese family policy benefits
Study: 32073874
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL V. odorata syrup every 12 hours for 4 weeks
Study: 32073874
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL placebo syrup every 12 hours for 4 weeks
Study: 33857782
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment
Study: 36446551
Drug: Diet or
Normalized name: T-Diet Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet or medication
Study: 35405352
Drug: PRN ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PRN ranibizumab or bevacizumab treatment
Study: 32800078
Drug: Combination Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination Nicotine Replacement Therapy (Nicotine Patch and Lozenge)
Study: 36099501
Drug: Estetrol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estetrol (15 mg) and Drospirenone (3 mg)
Study: 36099501
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 or 20 mcg) with Levonorgestrel (150 mcg)
Study: 36099501
Drug: Ethinylestradiol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (30 or 20 mcg) with Drospirenone (3 mg)
Study: 33152314
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling plus 800 mg/day of docosahexaenoic acid (Group 1)
Study: 33152314
Drug: Routine counseling
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine counseling plus 800 mg/day docosahexaenoic acid (Group 2)
Study: 33152314
Drug: Dietary counseling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counseling plus 200 mg/day docosahexaenoic acid (Group 3)
Study: 33152314
Drug: Routine counseling
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine counseling plus 200 mg/day docosahexaenoic acid (Group 4, control group)
Study: 33234219
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (rewarmed to normal body temperature 36° to 37°C)
Study: 34441888
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy treatment
Study: 32820851
Drug: Psilocybin (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (230 μg/kg p.o.)
Study: 35234828
Drug: Combined Individual
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Individual and Group Schema Therapy (IGST)
Study: 35234828
Drug: Predominantly Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predominantly Group Schema Therapy (PGST)
Study: 34937613
Drug: CTZ (LSTR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTZ (LSTR antibiotic paste)
Study: 35976802
Drug: Pulsed nonthermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy (RecoveryRx) applied for up to 30 days
Study: 35976802
Drug: Pulsed nonthermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy
Study: 34865333
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of warm acupuncture at back-shu points of five zang organs and escitalopram oxalate tablets (30 min each time, 5 times a week for 6 weeks)
Study: 34865333
Drug: Escitalopram oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram oxalate tablets (administered orally every day for 6 weeks)
Study: 34229509
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) supplemented with intensive principle-based correctional counseling (PBCC)
Study: 32567734
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid 250 mg and oral ranitidine 150 mg twice daily, plus topical fluocinolone‐based combination cream (FbTC) once daily.
Study: 32567734
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (calcium lactate and multivitamin) and topical fluocinolone‐based combination cream (FbTC) once daily.
Study: 34182150
Drug: Budesonide Oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Oral Suspension (BOS)
Study: 32696598
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) therapy (2 L/kg/min)
Study: 33162348
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of intravenous morphine during anesthetic induction
Study: 33162348
Drug: Conventional anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anesthesia without morphine
Study: 36428277
Drug: Moisturizer applied
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer applied three times daily on one side of the face
Study: 32321718
Drug: CPC634 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC634 (75 mg/m2)
Study: 32321718
Drug: Conventional docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional docetaxel (75 mg/m2)
Study: 39233210
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg daily
Study: 34743243
Drug: Silver-modified atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver-modified atraumatic restorative treatment (SMART) sealants
Study: 36682889
Drug: Niacin treatment
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin treatment
Study: 35437945
Drug: Crizotinib treatment
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib treatment with a low radiomics score
Study: 34588809
Drug: High-frequency impulse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency impulse therapy (HFIT)
Study: 33828241
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of iron (60 mg), folic acid (500 mcg), and cyanocobalamin (1000 mcg) for 90 days
Study: 33828241
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of iron, folic acid, and vitamin B12 for 90 days
Study: 32465627
Drug: Hybrid thrombolytic
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid thrombolytic approach (hTL) using alteplase infused at 1mg/min followed by maintenance infusion at 1mg/hour, median total alteplase dose was 74mg (IQR 48, 90mg).
Study: 34371880
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral vitamin A and D drops (1800 IU vitamin A and 600 IU vitamin D2) for 2 months
Study: 36112723
Drug: Probiotics (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (one capsule per day for 3 months)
Study: 34179971
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta (individualised fixed-dose regimen based on AMH level and body weight)
Study: 34179971
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta (individualised fixed-dose regimen)
Study: 32334541
Drug: Life Review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Review Therapy for Holocaust Survivors (LRT-HS) consisting of 20-25 sessions
Study: 34870587
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy with ≥ 4 hours of use on ≥ 70% of nights
Study: 34870587
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy with < 4 hours of use or < 70% of nights
Study: 33374791
Drug: Clobetasol oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol oral gel 0.05%
Study: 34603442
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenous before skin incision
Study: 32075228
Drug: Enzogenol® 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® 50 mg
Study: 32075228
Drug: Enzogenol® 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol® 400 mg
Study: 36760029
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received treatment including single surgery of bone grafting associated with periosteal releasing incision
Study: 34313093
Drug: Critically important
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically important antimicrobials administered sub-therapeutically for prophylaxis and growth enhancement purposes.
Study: 33710263
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (HT) including conjugated equine estrogens (E) alone for women without a uterus (n=560) and E plus medroxyprogesterone acetate (P) for those with an intact uterus (n=610)
Study: 35577478
Drug: Continue DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue DMARD therapy after first dose vaccination
Study: 35577478
Drug: Withhold DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withhold DMARD therapy after first dose vaccination
Study: 35577478
Drug: Continue DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue DMARD therapy after second dose vaccination
Study: 35577478
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DMARD therapy)
Study: 35577478
Drug: tsDMARD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: tsDMARD therapy
Study: 33974920
Drug: Pre-workout supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-workout supplement (SUPP)
Study: 36477362
Drug: sequential belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sequential belimumab + rituximab
Study: 35524760
Drug: Breast nurse
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast nurse intervention including education, literacy material, empathetic counselling, phone call reminders, and monitoring of medication refill.
Study: 34521217
Drug: Invasive management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive management (medical therapy + angiography and revascularization if feasible)
Study: 34521217
Drug: Conservative approach
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative approach (medical therapy alone with revascularization if medical therapy failed)
Study: 32986682
Drug: PF-06412562 (split
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562 (split dose 25+20mg)
Study: 32667582
Drug: Short-course hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course hyperthermic intraperitoneal chemotherapy (HIPEC) for 30 minutes
Study: 33781259
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy including six levels of rehabilitation exercises
Study: 33263702
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion speed (333mL/h)
Study: 33263702
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion speed (999mL/h)
Study: 37845604
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) angioplasty
Study: 35340225
Drug: Exercise prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescription (Control)
Study: 35713670
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (Tα1) 1.6 mg every 12 hours for the first 7 days and 1.6 mg once a day for the subsequent 7 days
Study: 32462427
Drug: Intravenous autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous autologous bone marrow-derived MSCs
Study: 32462427
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no MSC treatment)
Study: 33545758
Drug: Anti-PD-1/PD-L1 agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 agents
Study: 34329774
Drug: Resmetirom 80
Normalized name: resmetirom 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resmetirom 80 mg daily
Study: 34402728
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg drospirenone (DRSP)
Study: 34402728
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg desogestrel (DSG)
Study: 32485633
Drug: Hippotherapy (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (16 sessions of 30 minutes, twice a week for 8 weeks)
Study: 32392952
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surfactant administration (MISA)
Study: 32392952
Drug: Endotracheal intubation
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal intubation surfactant administration (EISA)
Study: 35039439
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 0.4 mL/kg of 0.25% ropivacaine
Study: 35039439
Drug: II/IH block
Approvals — FDA: no, EMA: no, PMDA: no
Description: II/IH block with 0.2 mL/kg of 0.25% ropivacaine
Study: 35039439
Drug: QLB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLB with 0.4 mL/kg of 0.25% ropivacaine
Study: 33947344
Drug: Ivermectin 200
Normalized name: ivermectin 200 ug / praziquantel 1.5 mg ORAL PASTE [Equimax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 200 mcg/kg/day for 5 days added to hydroxychloroquine + favipiravir + azithromycin
Study: 33947344
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment (hydroxychloroquine + favipiravir + azithromycin) without ivermectin
Study: 33947344
Drug: Reference treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference treatment without ivermectin
Study: 32616493
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires
Study: 34521568
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels (intervention not specified in terms of dosage or duration)
Study: 35295056
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with premolar extraction
Study: 35295056
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment without premolar extraction
Study: 35578182
Drug: Fremanezumab treatment
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab treatment
Study: 35683437
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (AT) 3 times a week for 8 weeks.
Study: 35569036
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550 (18 mg twice daily)
Study: 33079921
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% plus CXL
Study: 33079921
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5%
Study: 32927476
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of hypoglycemia (p-glucose < 2.9 mmol/L) followed by a euglycemic clamp
Study: 34129728
Drug: Lidocaine/tetracaine 7%/7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine 7%/7% peel cream (L/T‐pC) applied 45 minutes before laser treatment
Study: 34129728
Drug: Control (emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (emollient cream)
Study: 33406977
Drug: Thyroid peroxidase
Normalized name: Thyroid peroxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid peroxidase antibodies (TPOAb)
Study: 33406977
Drug: Thyroglobulin antibodies
Normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroglobulin antibodies (TgAb)
Study: 33235121
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with placebo
Study: 35550716
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy dressing